吉贝尔：参股子公司研发宫血间充质干细胞注射液适应症覆盖多种疾病

Core Viewpoint - The company is developing a stem cell injection (SC01009) for various diseases, including idiopathic pulmonary fibrosis, hepatitis B-related decompensated cirrhosis, and mild to moderate acute respiratory distress syndrome, with a focus on idiopathic pulmonary fibrosis currently undergoing Phase II clinical trials [1] Group 1 - The company has a stake in Zhejiang Shengchuang Precision Medical Technology Co., Ltd., which is working on the stem cell injection [1] - The indications for the stem cell injection include idiopathic pulmonary fibrosis, hepatitis B-related decompensated cirrhosis, and mild to moderate acute respiratory distress syndrome [1] - The Phase II clinical trial for idiopathic pulmonary fibrosis is currently in progress [1]